Use of sedative and analgesic agents in neurotrauma patients: Effects on cerebral physiology

Neurological Research

Volumn 23, Issue 2-3, 2001, Pages 237-259

  Rhoney, D H ^a   Parker D , Jr ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Analgesia; Intracranial pressure; Neurotrauma; Sedation

Indexed keywords

ALFENTANIL; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; DEXMEDETOMIDINE; DIAZEPAM; ETOMIDATE; FENTANYL; HALOPERIDOL; KETAMINE; LORAZEPAM; MIDAZOLAM; MORPHINE; NEUROLEPTIC AGENT; OPIATE; PENTOBARBITAL; PETHIDINE; PROPOFOL; REMIFENTANIL; SEDATIVE AGENT; SUFENTANIL; THIOPENTAL;

ARTICLE; BRAIN INJURY; BRAIN METABOLISM; BRAIN PERFUSION; CLINICAL TRIAL; DRUG EFFECT; HUMAN; INTENSIVE CARE UNIT; INTRACRANIAL PRESSURE; MEAN ARTERIAL PRESSURE; NERVOUS SYSTEM INJURY; NONHUMAN; PATIENT MONITORING; PLASMA PROTEIN BINDING; TRANQUILIZING ACTIVITY;

ANALGESICS; BRAIN INJURIES; HUMANS; HYPNOTICS AND SEDATIVES; INTRACRANIAL PRESSURE;

EID: 0035069845     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164101101198398     Document Type: Article

References (323)

1. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: An executive summary
2. Controlled sedation with alphaxalone/alphadolone
3. A research tool for measurement of recovery from sedation: The Vancouver Sedative Recovery Scale
4. Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients
5. Motor activity assessment scale: A valid and reliable sedation scale for use with mechanically ventilated patients in an adult surgical intensive care unit
6. Assessing sedation during intensive care unit ventilation with the Bispectral Index and the Sedation-Agitation Scale
7. Continuous monitoring of jugular bulb oxygen saturation and the effect of drugs on acting on cerebral metabolism
8. Practical pharmacokinetics as applied to our daily anesthesia practice
9. New concepts in pharmacokinetics and pharmacodynamics
10. A national survey of the use of sedating and neuromuscular blocking agents in the intensive care unit
11. Benzodiazepine receptor occupancy in vivo: Correlation with brain concentrations and pharmacodynamic actions
12. Aging increases pharmacodynamic sensitivity to the hypnotic effects of midazolam
13. Anesthetic drug interaction: An overview
14. A large-sample study of diazepam pharmacokinetics
15. Effect of omeprazole and cimetidine on plasma diazepam levels
16. Prolonged sedation due to accumulation of conjugated metabolites of midazolam
17. Midazolam kinetics
18. Accumulation of midazolam after repeated dosage in patients receiving mechanical ventilation in an intensive care unit
19. Age and nature of operation influence the pharmacokinetics of midazolam
20. Pharmacokinetics of midazolam in patients recovering from cardiac surgery
21. The influence of renal failure on the kinetics of intravenous midazolam: An in vitro and in vivo study
22. Dose of midazolam should be reduced during diltiazem and verapamil treatments
23. A potentially hazardous interaction between erythromycin and midazolam
24. The effects of systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
25. Kinetic and dynamic study of intravenous lorazepam: Comparison with intravenous diazepam
26. Effects of aging and liver disease in disposition of lorazepam
27. Effect of renal impairment and hemodialysis on lorazepam kinetics
28. Effect of neurotrauma on hepatic drug clearance
29. Systemic and coronary hemodynamic effects of diazepam in patients with normal and diseased coronary arteries
30. Negative inotropic effects of midazolam
31. Effects of diazepam and midazolam on baroreflex control of heart rate and on sympathetic activity in humans
32. Frequent hypoxemia and apnea after midazolam and fentanyl
33. Midazolam/propofol but not propofol alone reversibly depress the swallowing reflex
34. The effect of intravenously administered diazepam, midazolam and flumazenil on the sensitivity of upper airway reflexes
35. Intravenous midazolam for the treatment of refractory status epilepticus
36. Diazepam blocks metabolic and circulatory responses to local anesthetic-induced seizures
37. The effects of diazepam on cerebral blood flow and oxygen consumption in rats and its synergistic interaction with nitrous oxide
38. Cerebral effects of midazolam and idazepam
39. The effects of midazolam on cerebral blood flow and oxygen consumption and its interaction with nitrous oxide
40. Effects of diazepam on cerebral blood flow and oxygen uptake after head injury
41. Effects of midazolam on cerebral blood flow in human volunteers
42. Changes in cerebral blood flow velocity after intravenous diazepam
43. Cerebral vasomotor responsiveness to carbon dioxide is preserved during propofol and midazolam anesthesia in humans
44. Effects of midazolam on cerebral hemodynamics and cerebral vasomotor responsiveness to carbon dioxide
45. Diazepam and intracranial pressure
46. Effetti del midazolam sulla pressione intracranica e sulla pressione di perfusione cerebrale in pazienti affetti da pathologia intracranica di tipo espansivo sottoposti ad intervento neurochirurgico
47. Effetti sulla pressione intracranica di una benzodiaepina idrosolubile: II Midazolam
48. Intracranial pressure, mean arterial pressure, and heart rate following midazolam of thiopental in humans with brain tumors
49. Effect of bolus doses of midazolam on intracranial pressure and cerebral perfusion pressure in patients with severe head injury
50. Auditory and electroencephalographic effects of midazolam and alpha-hydroxy-midazolam in healthy subjects
51. Benzodiazepines protect mice from local anesthetic convulsions and deaths
52. Benzodiazepines protect hippocampal neurons from degeneration after transient cerebral ischemia: An ultrastructural study
53. Cerebral effects of high-dose midazolam and subsequent reversal with RO 15-1788 in dogs
54. Effects of a specific benzodiazepine antagonist (RO 15-1788) on cerebral blood flow
55. Effects of flumazenil on cerebral blood flow and oxygen consumption after midazolam anaesthesia for craniotomy
56. The effects of midazolam reversal by RO 15-1788 on cerebral perfusion pressure in patients with severe head injury
57. The touch of Morpheaus: Pre 20th century accounts of sleepy patients
58. Opiate structure and activity: A guide to understanding the receptor
59. Narcotic pharmacokinetics and dynamics: The basis of infusion applications
60. Pharmacokinetics of opioids in renal dysfunction
61. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis
62. Pharmacokinetics of morphine sulfate in patients with burns
63. Profound reduction in morphine clearance and liver blood flow in shock
64. Acute trauma alters morphine clearance
65. Central nervous system excitatory effects of meperidine in cancer patients
66. Accumulation of normeperidine, an active metabolite, in patients with renal failure or cancer
67. Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver
68. Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood
69. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update
70. Pharmacokinetics of fentanyl in congestive heart failure (CHF)
71. Alfentanil pharmacokinetics in patients with cirrhosis
72. Alfentanil infusion in patients requiring intensive care
73. The role of cytochrome P450 3A4 in alfentanil clearance
74. The pharmacokinetics of sufentanil in surgical patients
75. Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients
76. The pharmacokinetics and pharmacodynamics of remifentanil in volunteers with severe hepatic or renal dysfunction
77. The effects of meperidine, promethazsine, and cholorpromazine on pulmonary and systemic circulation
78. A comparison of the circulatory effects in man of the analgesics fentanyl, pentazocine and pethidine
79. ED50 of alfentanil for induction of anesthesia in unpremedicated young adults
80. Protective effect of vagotonic action of morphine sulfate on ventricular vulnerability
81. Cardiovascular effects of high-dose fentanyl anaesthesia
82. Effects of fentanyl and diazepam in dogs deprived of autonomic tone
83. Histamine release by narcotics and muscle relaxants in humans
84. Disruption of the rhythmic activity of the medullary inspiratory neurons and phrenic nerve by fentanyl and reversal with nalbuphine
85. Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man
86. Opiate action in the pulmonary circulation
87. Localization of brain stem sites which mediate alfentanil-induced muscle rigidity in the rat
88. Regulation of gastrointestinal function by multiple opioid receptors
89. Common bile duct pressure changes after fentanyl, morphine, meperidine, butorphanol, and naloxone
90. Sulfentanil, alfentanil, and fentanyl: Impact on cerebrospinal fluid pressure in patients with brain tumors
91. Effects of sufentanil on cerebral blood flow, cerebral blood flow velocity, and metabolism in dogs
92. Effect of morphine and n-allylnormorphine on cerebral hemodynamics and oxygen metabolism
93. Cerebral blood flow and metabolism during morphine-nitrous oxide anesthesia in man
94. The effects of high dose fentanyl on cerebral circulation and metabolism in rats
95. Effects of fentanyl, droperidol, and innovar on canine cerebral metabolism and blood flow
96. Effects of fentanyl on peripheral and cerebral hemodynamics in neonatal lambs
97. The effect of fentanyl, sufentanil, and alfentanil on cerebral arterioles in piglets
98. Effects of fentanyl versus sufentanil in equianesthetic doses on middle cerebral artery blood flow velocity
99. Sufentanil does not increase cerebral blood flow in healthy volunteers
100. The effect of alfentanil on cerebral blood flow velocity and intracranial pressure during isoflurane-nitrous oxide anesthesia in humans
101. Sulfentanil increases intracranial pressure in patients with head trauma
102. Fentanyl and sufentanil increase intracranial pressure in head trauma patients
103. Sufentanil, fentanyl, and alfentanil in head trauma patients: A study on cerebral hemodynamics
104. Effect of sufentanil on intracranial pressure in neurosurgical patients
105. Effects of sufentanil on cerebral hemodynamics and intracranial pressure with brain injury
106. Effects of alfentanil on cerebral haemodynamics in an experimental model of traumatic brain injury
107. Effects of sufentanil on cerebral circulation and metabolism in dogs
108. Alfentanil induced hypermetabolism, seizure, and histopathology in rat brain
109. Opioid neurotoxicity: Fentanyl dose-response effects in rats
110. Cerebral hemodynamic effects of morphine and fentanyl in patients with severe head injury: Absence of correlation to cerebral autoregulation
111. Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy
112. Intact cerebral blood flow reactivity during remifentanil/nitrous oxide anesthesia
113. Safety and feasibility of continuous infusion of remifentanil in the neurosurgical intensive care unit
114. Convulsion: An unusual response to intravenous fentanyl administration
115. Grand-mal seizure after fentanyl administration
116. Seizure-like movements during a fentanyl infusion with absence of seizure activity in a simultaneous EEG recording
117. Absence of seizure during induction of anesthesia with high-dose fentanyl
118. Electroencephalographic effects of sufentanil anaesthesia in man
119. Effects of high dose fentanyl anesthesia on the electroencephalogram
120. Luminal Bei Epilepsy
121. Hypnotics and sedatives; Ethanol
122. Pentobarbital pharmacokinetics in patients with severe head injury
123. High dose barbiturates for intracranial pressure control
124. The role of body fat in limiting the duration of action of thiopental
125. Pharmacokinetics of high-dose pentobarbital in severe head trauma
126. Pharmacodynamics and pharmacokinetics of thiopental
127. Barbiturates in brain ischaemia
128. Barbiturate therapy in the management of cerebral ischaemia
129. Pentobarbital coma in neurosurgical patients: Nutrition considerations
130. Guidelines for the management of severe head injury. The use of barbiturates in the control of intracranial hypertension
131. Electroencephalographic activity and serum and cerebrospinal fluid pentobarbital levels in determining the therapeutic end point during barbiturate coma
132. Management of status epilepticus
133. Mechanisms of cerebral protection by pentobarbital and nizofenane correlated with the course of local cerebral blood flow changes
134. The University of Toronto Head Injury Treatment Study: A prospective, randomized comparison of pentobarbital and mannitol
135. Failure of prophylactic barbiturate coma in the treatment of severe head injury
136. High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury
137. Barbiturates in focal ischemia of primate cortex: Effects on blood flow distribution, evoked potential and extracellular potassium
138. The free radical pathology and the microcirculation in the major central nervous system
139. Current concepts in cerebral protection
140. Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest
141. Barbiturate-induced coma to protect against cerebral ischemia and increased intracranial pressure
142. Barbiturates for protection from cerebral ischemia in aneurysm surgery
143. Barbiturates for cerebral aneurysm surgery
144. Enhancement by propofol of the γ-aminobutyric acid A response in dissociated hippocampal pyramidal neurons of the rat
145. Biochemical and electrophysiological evidence that propofol enhances GABAergic transmission in the rat brain
146. Disposition of propofol in patients undergoing surgery. A comparison in men and women
147. The pharmacokinetics of propofol versus age
148. Disposition of propofol administered as constant rate intravenous infusions in humans
149. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthesia
150. Pharmacokinetics of propofol (Diprivan) in elderly patients
151. Pharmacokinetic model driven infusion of propofol in children
152. The induction of anesthesia with propofol (Diprivan) compared in normal and renal failure patients
153. Pharmacokinetics and protein binding of propofol in patients with cirrhosis
154. Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients
155. Pharmacokinetics of propofol during and after long term continuous infusion for maintenance of sedation in ICU patients
156. Propofol for long-term sedation in the intensive care unit
157. Propofol in patients needing long-term sedation in intensive care: An assessment of the development of tolerance. A pilot study
158. Pharmacokinetics of propofol: Influence of fentanyl administration
159. Pharmacokinetic interaction of propofol and fentanyl: Single bolus injection study
160. Haemodynamic changes during anaesthesia induced and maintained with propofol
161. The haemodynamic effects of thiopentone and propofol
162. Effect of propofol anesthesia on baroreflex activity in humans
163. The cardiorespiratory effects of ICI 35 868 in patients with valvular disease
164. Ventilatory effects of propofol during induction of anesthesia. Comparison with thiopentone
165. Some ventilatory effects of propofol as sole anesthetic agent
166. The effect of halothane, propofol and thiopentone on peripheral airway reactivity
167. Prolonged sedation of critically ill patients with midazolam or propofol: Impact on weaning and costs
168. Propofol-induced pancreatitis: Recurrence of pancreatitis after rechallenge
169. Elevated pancreatic enzymes after extended propofol therapy
170. Effects of Disoprivan on cerebral blood flow, cerebral oxygen consumption and cerebral vascular reactivity
171. Intracranial pressure after propofol and thiopental administration in patients with severe head trauma
172. Effect of propofol (Disoprivan) on intracranial pressure. Preliminary results
173. Effect of propofol on cerebrospinal fluid pressure and cerebral perfusion pressure in patients undergoing craniotomy
174. Effect of propofol on cerebral blood flow and metabolism in man
175. Cerebral autoregulation is maintained during propofol-nitrous oxide anesthesia in humans
176. 2 and cerebral blood flow velocity
177. Effect of propofol on elevated intracranial pressure. Preliminary results
178. Effects of propofol on cerebral hemodynamics and metabolism in patients with brain trauma
179. The effects of propofol on cerebral high energy metabolites, lactate, and glucose in normoxic and severely hypoxic rats. The effects of propofol on cerebral high energy metabolites, lactate, and glucose in normoxic and severely hypoxic rats
180. A comparison of the cerebral protective effects of propofol, thiopental, and halothane in temporary feline focal cerebral ischemia
181. Propofol infusion for sedation of patients with head injury in intensive care: A preliminary report
182. Comparison of the effects of 24 hour propofol or fentanyl infusions on intracranial pressure
183. Propofol sedation in severe head injury fails to control high ICP, but reduces brain metabolism
184. Propofol in the treatment of moderate and severe head injury: A randomized, prospective, double-blinded pilot trial
185. The comparative effects of propofol, thiopentone, and diazepam administered intravenously on pentylenetetrazol seizure threshold in the rabbit
186. Propofol vs. thiopental for treating bupivacaine induced seizures in rats
187. Propofol infusion for the treatment of status epilepticus
188. Successful use of propofol in status epilepticus, letter
189. Electroencephalographic burst suppression by propofol infusion in humans: Hemodynamic consequences
190. Propofol and the electroencephalogram
191. Multiple seizures following re-exposure to propofol
192. The effects of propofol on brain electrical activity, neurologic outcome and neuronal damage following incomplete ischemia in rats
193. Comparative effects of propofol and halothane on outcome from temporary middle cerebral artery occlusion in the rat
194. Comparison of the effects of propofol and pentobarbital on neurologic outcome and cerebral infarct size after temporary focal ischemia in the rat
195. The widely used anesthetic agent propofol can replace α-tocopherol as an antioxidant
196. Propofol protect cultured rat hippocampal neurons against n-methyl-D-aspartate receptor-mediated glutamate toxicity
197. The nonhypnotic therapeutic applications of propofol
198. Increase in the antioxidant capacity of plasma during propofol anesthesia
199. Mechanisms of etomidate potentiation of GABA-A receptor-gated currents in cultured postnatal hippocampal neurons
200. Profile of etomidate
201. Cerebral blood flow and metabolism during etomidate anesthesia in man
202. Etomidate: A new intravenous anesthetic induction agent
203. Pharmacokinetics of etomidate
204. Clinical use of etomidate for anesthesia induction: A preliminary report
205. Comparison of a new formulation of etomidate with thiopental - Side effects and awakening times
206. A review of etomidate for rapid sequence intubation in the emergency department
207. Increased sensitivity to etomidate in the elderly: Initial distribution versus altered brain response
208. Vascular effects of etomidate administered for electroencephalographic burst suppression in humans
209. Sympathetic responses to induction of anesthesia in humans with propofol or etomidate
210. Comparison of the ventilatory effects of etomidate and methohexital
211. The effect of propofol on adrenocortical steroidogenesis. A comparative study with etomidate and thiopental
212. Different inhibitory effect of etomidate and ketoconazole on the human adrenal steroid biosynthesis
213. Differential effects of the imidazole derivatives etomidate, ketoconazole, and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells
214. The role of ascorbic acid in etomidate toxicity
215. Etomidate inhibits adrenocortical function in surgical patients
216. Mortality amongst multiple trauma patients admitted to an intensive therapy unit
217. Influence of sedation on mortality in critically ill multiple trauma patients
218. Adrenocortical function in critically ill patients 24 hr after a single dose of etomidate
219. Solvent for etomidate may cause pain and adverse effects
220. Toxogical evaluation of certain food additives with a review of general principles and of specifications
221. Propylene glycol toxicity following continuous etomidate infusion for the control of refractory cerebral edema
222. Propylene glycol toxicity caused by prolonged infusion of etomidate
223. Cerebral protective effects of etomidate: Experimental and clinical aspects
224. Haemolysis after etomidate: Comparison of propylene glycol and lipid formulations
225. A comparison of two formulations for etomidate, 2-hydroxypropyl-β-cyclodextrin and propylene glycol
226. Use of etomidate, temporary arterialocclusion, and intraoperative angiography in surgical treatment of large and giant cerebral aneurysms
227. Etomidate: A clinical and electro-encephalographic comparison with thiopental
228. Pro- and anticonvulsant effects of anesthetics (part II)
229. Intracranial pressure during induction of anaesthesia and tracheal intubation with etomidate-induced EEG burst suppression
230. Etomidate infusions for the control of refractory status epilepticus
231. Effect of etomidate on the electroencephalogram of patients with epilepsy
232. Excitatory effects and electroencephalographic correlation of etomidate, thiopental, methohexital, and propofol
233. Activation of epileptogenic activity by etomidate
234. Cerebral blood flow and metabolism during etomidate anaesthesia in man
235. The effect of etomidate on intracranial pressure and cerebral perfusion pressure
236. Cerebral electrical activity influences the effects of etomidate on cerebral perfusion pressure in traumatic coma
237. Comparison of etomidate and althesin in the reduction of increased intracranial pressure after head injury
238. Preservation of cerebral metabolites by etomidate during incomplete cerebral ischemia in dogs
239. Brain protective properties of etomidate and flunarizine
240. Etomidate reduces ischemia-induced glutamate release in the hippocampus in rats subjected to incomplete forebrain ischemia
241. An opioid receptor mediation of ketamine analgesia
242. Neuronal mechanisms of ketamine-induced anesthesia
243. Effects of ketamine on nociceptive cells in the medial medullary reticular formation of the cat
244. Molecular actions of racemic ketamine on human CNS sodium channels
245. Effects of ketamine on sensory perception: Evidence for the role of N-methyl-D-aspartate receptors
246. Evidence of a role for NMDA receptors in pain perception
247. The effects of ketamine on the excitation and inhibition of dorsal horn WDR neuronal activity induced by bradykinin injection into the femoral artery in cats after spinal cord transection
248. The pharmacokinetics and analgesic effect of ketamine in man
249. Biotransformation and disposition of ketamine
250. Interaction of ketamine and halothane in rats
251. Coronary blood flow and myocardial oxygen consumption in patients during induction of anesthesia with droperidol/fentanyl or ketamine
252. Effects of ketamine on cardiovascular responses mediated by N-methyl-D-aspartate receptor in the rat nucleus tractus solitarius
253. Cardiovascular effects of centrally administered ketamine in goats
254. Counteraction of circulatory side effects of ketamine by treatment with diazepam
255. The cardiovascular response to ketamine: The effects of clonidine and lignocaine
256. Ketamine depresses myocardial contractility as evaluated by the preload recruitable stroke work relationship in chronically instrumented dogs with autonomic nervous system blockade
257. Comparison of the inotropic action of morphine and ketamine studied in canine cardiac muscle
258. Response to hypercapnia under ketamine anesthesia
259. Ketamine in the anesthetic management of asthmatic patients
260. Intracranial cerebrospinal fluid pressure in man during ketamine anesthesia
261. Ketamine anesthesia in patients with intracranial pathology
262. Ketamine-induced intracranial hypertension
263. Effects of ketamine on canine cerebral blood flow and metabolism: Modification by prior administration of thiopental
264. Ketamine/diazepam infusion anaesthesia with special attention to the effect on cerebrospinal fluid pressure and arterial blood pressure
265. Ketamine for analgosedative therapy in intensive care treatment of head-injured patients
266. Ketamine decreases intracranial pressure and electroencephalographic activity in traumatic brain injury patients during propofol sedation
267. Ketamine does not increase cerbral blood flow velocity or intracranial pressure during isoflurane nitrous oxide anesthesia in patients undergoing craniotomy
268. Modification of ketamine-induced intracranial hypertension in neurosurgical patients by pretreatment with midazolam
269. Cerebral blood flow and metabolism following ketamine administration
270. Pharmacologic effects of Cl-581, a new dissociative anesthetic in man
271. Ketamine induced electroconvulsive phenomena in the human limbic and thalamic regions
272. Ketamine anesthesia in brain-damaged epileptics
273. Pharmacokinetics of haloperidol: An update
274. The pharmacokinetics of droperidol in anesthetized patients
275. Absorption, metabolism and excretion of droperidol by human subjects following intramuscular and intravenous administration
276. Circulatory and respiratory response to tilt with pentazocine (Win 20, 228), droperidol (R4749), droperidol-fentanyl (Innovar), and methotrimeprazine in normal healthy male subjects
277. Cardiovascular effects of droperidol during enflurane and enflurane-nitrous oxide anesthesia in man
278. A study of some of the pharmacologic actions of droperidol
279. Measurements of anti-arrhythmic potency of drugs in man: Effects of dehydrobenzperidol
280. Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients
281. The association between intravenous haloperidol and torsade de pointes
282. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill
283. Torsade de pointes associated with intravenous haloperidol in critically ill patients
284. Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: Is HPTP an intermediate?
285. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes
286. Neuroleptic malignant syndrome with intravenous haloperidol
287. Neuroleptic malignant syndrome in a trauma patient
288. Effects of fentanyl, droperidol, and Innovar on canine cerebral metabolism and blood flow
289. Neuroleptics and continuous measurement of intracranial pressure
290. Cerebral blood flow, cerebrospinal fluid pressure and EEG activity during neuroleptanalgesia induced with dehydrobenzperidol and phenoperidine
291. C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment
292. Agitation in closed head injury: Haloperidol effects on rehabilitation outcome
293. Direct coronary and cerebral vascular responses to dexmedetomidine. Significance of endogenous nitric oxide synthesis
294. Anesthetic and hemodynamic effects of the steroisomers of medetomidine, an alpha-2 adrenergic agonist, inhalothane-anesthetized dogs
295. Dexmedetomidine diminishes halothane anesthetic requirements in rats through a postsynaptic alpha-2 adrenergic receptor
296. 2-adrenoceptor agonists in rats
297. Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 1: Pharmacodynamic and pharmacokinetic interactions
298. Dexmedetomidine
299. Dose-ranging study to evaluated the effects of dexmedetomidine on sedation
300. Pharmacokinetics of dexmedetomidine in patients with hepatic failure
301. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6)
302. Effects of IV dexmedetomidine in humans. II. Hemodynamic changes
303. 2 adrenergic agonists in cardiovascular anesthesia
304. 2-adrenoceptor agonist, on hemodynamic control mechanisms
305. 2-adrenergic mechanisms in coronary vasoconstriction
306. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate
307. Ventilatory effects of dexmedetomidine in dogs
308. Pharmacologic properties of prejunctional alpha-adrenoceptors in isolated feline middle cerebral arteries: Comparison with the postjunctional alpha-adrenoceptors
309. Distribution of alpha 2 agonist binding sites in the rat and human central nervous system: Analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents
310. The effect of lesions in the locus coeruleus on the physiological response of the cerebral blood flow vessels in cats
311. A hypnotic resonse to dexmedetomidine, an alpha-2 agonist, is mediated in the locus coeruleus in rats
312. 2-agonist, on cerebral blood flow and oxygen consumption during halothane anesthesia in dogs
313. Dexmedetomidine, an alpha-2 adrenergic agonist, decreases cerebral blood flow in the isoflurane-anesthetized dog
314. 2-Adrenergic agonist effects on normocapnic and hypercapnic cerebral blood flow in the dog are anesthetic dependent
315. Intracranial pressure effects of dexmedetomidine in rabbits
316. Dexmedetomidine decreases seizure threshold in a rat model of experimental generalized epilepsy
317. Dexmedetomidine decreases cerebral blood flow velocity in humans
318. Interaction of catecholamines and nitrous oxide ventilation during incomplete brain ischemia in rats
319. 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia
320. 2-adrenergic antagonist atipamezole
321. 2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia
322. Intraventricular dexmedetomidine decreases cerebral blood flow during normoxia and hypoxia in dogs